【项目简介】
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.
 
【检验原理】
本试剂盒采用双抗体夹心ELISA法。酶标微孔板上预包被有抗人VEGFR3抗体，当加入标准品和待测样本时，标准品和待测样本中的人VEGFR3会和该抗体结合。洗板后，游离的其他成分被洗去，加入辣根过氧化物酶标记的的抗人VEGFR3抗体可与被酶标板捕获的人VEGFR3结合，形成“包被抗人VEGFR3抗体+人VEGFR3+抗人VEGFR3抗体-HRP”免疫复合物。当加入TMB显色底物后，复合物上连接的HRP催化底物反应，生成蓝色产物，终止反应后变为黄色。在450nm处测定OD值，人VEGFR3浓度与OD450值之间呈正比，可通过绘制标准曲线求出标本中人VEGFR3的浓度。